Symbol="ELDN"
AssetType="Common Stock"
Name="Eledon Pharmaceuticals Inc"
Description="Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral sclerosis (ALS) who require organ or cell transplantation. The company is headquartered in Irvine, California."
CIK="1404281"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="19900 MACARTHUR BLVD., SUITE 550, IRVINE, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="28583900"
EBITDA="-36862000"
PERatio="None"
PEGRatio="None"
BookValue="5.43"
DividendPerShare="0"
DividendYield="0"
EPS="-5.95"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.21"
ReturnOnEquityTTM="-0.769"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-5.95"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="18.4"
TrailingPE="-"
ForwardPE="2.19"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.248"
EVToRevenue="-"
EVToEBITDA="0.776"
Beta="1.899"
num_52WeekHigh="3.928"
num_52WeekLow="1.2"
num_50DayMovingAverage="1.512"
num_200DayMovingAverage="2.265"
SharesOutstanding="22507000"
DividendDate="2020-10-05"
ExDividendDate="None"
symbol="ELDN"
open="1.23"
high="1.33"
low="1.20"
price="1.21"
volume="21885.00"
latest_trading_day="2023-08-09"
previous_close="1.28"
change="-0.07"
change_percent="-5.4688%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="87"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="13"
Volume_recent_avg="144099"
Change_recent_avg="-0.01"
Delta_recent_avg="0.22"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-0.67"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="13"
Aroon_momentum_negative="87"
image_negative_thumbnail_id_1="1102"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0135.jpeg"
image_negative_thumbnail_id_2="112"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0064.jpeg"
image_neutral_thumbnail_id_1="536"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0063.jpeg"
image_neutral_thumbnail_id_2="523"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0076.jpeg"
image_positive_thumbnail_id_1="954"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0116.jpeg"
image_positive_thumbnail_id_2="667"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0041.jpeg"
image_professor_thumbnail_id_1="1188"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
image_professor_thumbnail_id_2="1179"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0013.jpeg"
